BioCryst and Clearside partner to develop avoralstat for DME via SCS Microinjector; $5M upfront

BIOCRYST PHARMACEUTICALS INC

License agreement for avoralstat for diabetic macular edema using Clearside's SCS Microinjector.
BioCryst pays $5M upfront; Clearside eligible for up to $30M in clinical/regulatory milestones and up to $47.5M in sales milestones.
Avoralstat previously safe in Phase 3 HAE trial; high potency and low solubility suited for suprachoroidal delivery.
DME is common cause of vision loss; one-third of patients don't respond to anti-VEGF therapies.
BioCryst to host R&D Day today at 1:00 pm ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.